January 12, 2018 01:26 PM EST
Pharma

Scoop: With its NDA in lim­bo, Iron­shore ex­ecs shut­tered the AD­HD biotech

John Carroll

Editor & Founder

A year ago Iron­shore Phar­ma­ceu­ti­cals ex­ecs trum­pet­ed the news that they had lined up $200 mil­lion in fi­nanc­ing to launch a new AD­HD drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

Ab­b­Vie makes an­oth­er small I&I ac­qui­si­tion, buy­ing Nim­ble for $200M

McK­in­sey hit with a $650M fine for de­ceiv­ing US about opi­oid con­sult­ing work

Xaira hires for­mer Roche ex­ec as CMO; 'Tis the sea­son for re­tire­ments at Al­ny­lam, Re­gen­eron

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times